37225
document
A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin 's lymphoma . Some reports have suggested that rituximab administration before PBSC mobilization may adversely affect PBSC yield . We conducted a prospective randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab to determine whether its addition would adversely affect CD34+ cell yield in patients with non-Hodgkin 's lymphoma . Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide , G-CSF and rituximab . There were no adverse consequences of rituximab on CD34+ cell yield , or hematopoietic recovery or immunoglobulin levels after transplantation .
37226
Intervention_Pharmacological
rituximab
37227
Intervention_Pharmacological
etoposide and G-CSF with or without rituximab
37228
Intervention_Pharmacological
etoposide
37229
Intervention_Pharmacological
etoposide , G-CSF and rituximab
37230
Outcome_Physical
CD34+ cell yield , or hematopoietic recovery or immunoglobulin levels
37231
Participant_Condition
B-cell non-Hodgkin 's lymphoma
37232
Participant_Condition
non-Hodgkin 's lymphoma
37233
Participant_Sample-size
Twenty seven